Australian hearing device emphasizes discreet aid

A new discreet hearing aid by Australia-based Cochlear Limited is set to enter the market this fall.

The new Kanso Sound Processor is an off-the-ear hearing device designed to deliver the same quality of hearing as other behind-the-ear products. ("Kanso" means simplicity in Japanese.)

The wireless device has only a single on/off button, dual microphones and can be easily hidden under or blended within hair, Cochlear said in a statement. It will come in eight colors.

“Through customer feedback, we identified the need for a new solution that provides the advanced technology and hearing performance of our latest cochlear implant sound processor, which is worn behind the ear, in an easy and discreet design with access to wireless and water accessories, all without losing the high-quality hearing experience our customers expect from our products,” said Tony Manna, president of Cochlear North America, in a statement.

The Kanso Sound Processor was designed with the same technology used in other Cochlear devices like the Nucleus 6 Sound Processor, which allows the processor to automatically adjust to different listening environments. The Kanso model also has built-in wireless streaming technology so that users can take calls, listen to music and connect it to video viewing devices.

 

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.